Las Vegas: Can Collaboration Speed Drug Discovery for FTD?
November 2011 in San Diego.—Esther Landhuis. This concludes a three-part series. See also Part 1 and Part
379 RESULTS
You searched Esther
Sort By:
November 2011 in San Diego.—Esther Landhuis. This concludes a three-part series. See also Part 1 and Part
of disease,” Robert Nagele told ARF.—Esther Landhuis None
more mechanistic work and trying to design analogs, Barnham said.—Esther Landhuis None
cholesterol but on the whole [mevalonate] pathway. The implications of that could be detrimental.”—Esther
(Becker et al., 2011).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3342
people with neuropathic pain (Boccard et al., 2013).—Esther Landhuis None
Sciences (see Science article).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3413
and pathways.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3497 Alzheimer's
diseases,” Dobson said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3504 Alzheimer's
influence disease risk through multiple mechanisms, can also be problematic.—Esther Landhuis None
sequencing-based platforms,” Cookson said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3604
consider testing them in disease models, she said.—Esther Landhuis None
system waste products,” the authors write.—Esther Landhuis None
story).—Esther Landhuis None Immune Related Microglia/Astrocyte Growth Factors and Growth Factor Receptors
strengthen the rationale for blocking the tau-fyn association as a therapeutic approach.—Esther Landhuis None